Kovack Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $322K | Sell |
5,793
-17
| -0.3% | -$921 | 0.02% | 733 |
|
|
2025
Q4 | $285K | Buy |
+5,810
| New | +$271K | 0.01% | 773 |
|
|
2024
Q2 | – | Sell |
-5,312
| Closed | -$228K | – | 583 |
|
|
2024
Q1 | $228K | Sell |
5,312
-394
| -7% | -$16.2K | 0.03% | 410 |
|
|
2023
Q4 | $211K | Sell |
5,706
-2,360
| -29% | -$84.7K | 0.03% | 511 |
|
|
2023
Q3 | $292K | Sell |
8,066
-3,257
| -29% | -$116K | 0.04% | 399 |
|
|
2023
Q2 | $404K | Buy |
11,323
+2,533
| +29% | +$90.9K | 0.05% | 344 |
|
|
2023
Q1 | $313K | Buy |
8,790
+871
| +11% | +$30.5K | 0.04% | 400 |
|
|
2022
Q4 | $278K | Buy |
7,919
+267
| +3% | +$8.89K | 0.04% | 421 |
|
|
2022
Q3 | $225K | Sell |
7,652
-3,138
| -29% | -$119K | 0.03% | 492 |
|
|
2022
Q2 | $587K | Buy |
10,790
+3,372
| +45% | +$186K | 0.08% | 275 |
|
|
2022
Q1 | $403K | Buy |
7,418
+136
| +2% | +$7.39K | 0.04% | 444 |
|
|
2021
Q4 | $401K | Sell |
7,282
-852
| -10% | -$44.3K | 0.04% | 434 |
|
|
2021
Q3 | $388K | Buy |
8,134
+943
| +13% | +$47.4K | 0.04% | 438 |
|
|
2021
Q2 | $358K | Sell |
7,191
-1,183
| -14% | -$56.8K | 0.04% | 446 |
|
|
2021
Q1 | $374K | Buy |
8,374
+526
| +7% | +$23.9K | 0.05% | 384 |
|
|
2020
Q4 | $361K | Buy |
7,848
+1,218
| +18% | +$55.9K | 0.05% | 346 |
|
|
2020
Q3 | $312K | Buy |
+6,630
| New | +$332K | 0.06% | 325 |
|
|
2020
Q2 | – | Sell |
-4,622
| Closed | -$219K | – | 512 |
|
|
2020
Q1 | $219K | Sell |
4,622
-5,934
| -56% | -$317K | 0.05% | 354 |
|
|
2019
Q4 | $620K | Sell |
10,556
-338
| -3% | -$18.8K | 0.11% | 204 |
|
|
2019
Q3 | $581K | Sell |
10,894
-3,196
| -23% | -$164K | 0.12% | 202 |
|
|
2019
Q2 | $705K | Sell |
14,090
-1,365
| -9% | -$68.5K | 0.16% | 150 |
|
|
2019
Q1 | $807K | Sell |
15,455
-1,003
| -6% | -$50.1K | 0.2% | 127 |
|
|
2018
Q4 | $786K | Buy |
16,458
+172
| +1% | +$8.47K | 0.23% | 104 |
|
|
2018
Q3 | $818K | Buy |
16,286
+772
| +5% | +$39.2K | 0.21% | 120 |
|
|
2018
Q2 | $782K | Buy |
15,514
+676
| +5% | +$34K | 0.22% | 121 |
|
|
2018
Q1 | $725K | Sell |
14,838
-626
| -4% | -$29.2K | 0.18% | 135 |
|
|
2017
Q4 | $686K | Sell |
15,464
-449
| -3% | -$20.7K | 0.17% | 143 |
|
|
2017
Q3 | $808K | Sell |
15,913
-2,241
| -12% | -$114K | 0.27% | 93 |
|
|
2017
Q2 | $978K | Buy |
18,154
+1,768
| +11% | +$94.3K | 0.31% | 68 |
|
|
2017
Q1 | $864K | Sell |
16,386
-129
| -0.8% | -$6.54K | 0.34% | 67 |
|
|
2016
Q4 | $795K | Sell |
16,515
-1,763
| -10% | -$87.1K | 0.38% | 60 |
|
|
2016
Q3 | $985K | Buy |
18,278
+207
| +1% | +$11.3K | 0.48% | 48 |
|
|
2016
Q2 | $979K | Sell |
18,071
-192
| -1% | -$10.1K | 0.52% | 41 |
|
|
2016
Q1 | $926K | Sell |
18,263
-887
| -5% | -$44.2K | 0.58% | 40 |
|
|
2015
Q4 | $966K | Buy |
19,150
+36
| +0.2% | +$1.83K | 0.64% | 38 |
|
|
2015
Q3 | $919K | Buy |
19,114
+11,615
| +155% | +$605K | 0.64% | 36 |
|
|
2015
Q2 | $390K | Buy |
7,499
+807
| +12% | +$45.4K | 0.28% | 92 |
|
|
2015
Q1 | $386K | Buy |
+6,692
| New | +$384K | 0.33% | 76 |
|
Other funds holding GSK
JEST
Kovack Advisors's GSK Position: Q1 2026 in Review
Kovack Advisors reduced its GSK (GSK) stake by 0.29% in Q1 2026, selling an estimated $921 and leaving 5,793 shares worth $322K. The position accounts for 0.02% of the portfolio, ranked #733.
Kovack Advisors first reported a position in GSK in Q1 2015 and has held it in 38 quarters since. The position peaked at $985K in Q3 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Kovack Advisors held 5,793 shares of GSK worth $322K as of Q1 2026.
- Kovack Advisors sold 17 GSK shares in Q1 2026, an estimated $921.
- GSK made up 0.02% of Kovack Advisors's portfolio in Q1 2026, its #733 holding.
- Kovack Advisors first reported a position in GSK in Q1 2015 and has held it in 38 quarters since.
- Kovack Advisors's GSK position peaked at $985K in Q3 2016.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.